Remdesivir
- Generic Name
- Remdesivir
- Brand Names
- Veklury
- Drug Type
- Small Molecule
- Chemical Formula
- C27H35N6O8P
- CAS Number
- 1809249-37-3
- Unique Ingredient Identifier
- 3QKI37EEHE
- Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp)...
- Indication
Remdesivir is indicated for the treatment of adult and pediatric patients 28 days of age and older and weighing at least 3 kg for coronavirus disease 2019 (COVID-19) infection requiring hospitalization. It is also indicated for the treatment of non-hospitalized patients with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, ...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Remdesivir in Adults With Covid-19: Mansoura University Hospital Experience
- Conditions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 300
- Registration Number
- NCT04728880
- Locations
- 🇪🇬
Mansoura University Hospital, Mansoura, Dakahliya, Egypt
Antiviral Drugs on the Treatment of SARS-CoV-2
- Conditions
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Astana Medical University
- Target Recruit Count
- 150
- Registration Number
- NCT04727775
- Locations
- 🇰🇿
Semey Medical University, Semey, Kazakhstan
🇰🇿Aidos Konkaev, Astana, Kazakhstan
Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Nepal Health Research Council
- Target Recruit Count
- 676
- Registration Number
- NCT04694612
- Locations
- 🇳🇵
Charak Memorial Hospital, Pokhara, Gandaki, Nepal
🇳🇵Armed Police Force Hospital, Kathmandu, Bagmati, Nepal
Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
- Conditions
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- M Abdur Rahim Medical College and Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT04693026
- Locations
- 🇧🇩
M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- M Abdur Rahim Medical College and Hospital
- Target Recruit Count
- 205
- Registration Number
- NCT04678739
- Locations
- 🇧🇩
Chattogram General Hospital, Chittagong, Bangladesh
🇧🇩Cox's Bazar 250 Bed District Sadar Hospital, Cox's Bazar, Bangladesh
🇧🇩M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh
Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study
- Conditions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Nepal Health Research Council
- Target Recruit Count
- 2000
- Registration Number
- NCT04669990
- Locations
- 🇳🇵
Seti Provincial Hospital, Dhangadi, Nepal
🇳🇵BP Koirala Institute of Health Sciences (BPKIHS), Dharān Bāzār, Nepal
🇳🇵Bheri Provincial Hospital, Nepalgunj, Nepal
IFN-beta 1b and Remdesivir for COVID19
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 100
- Registration Number
- NCT04647695
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments
- Conditions
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- The University of The West Indies
- Target Recruit Count
- 100
- Registration Number
- NCT04647669
- Locations
- 🇯🇲
Univeristy of the West Indies, Kingston, Jamaica
Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-06-28
- Target Recruit Count
- 1010
- Registration Number
- NCT04640168
- Locations
- 🇺🇸
Cedars Sinai Medical Center, West Hollywood, California, United States
🇺🇸University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States
🇺🇸University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States
Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19)
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Dr. Md. Alimur Reza
- Target Recruit Count
- 60
- Registration Number
- NCT04596839
- Locations
- 🇧🇩
Combined Military Hospital, Dhaka, Bangladesh
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.